Skip to main content

Table 2 Drug interactions at 50% killing between cisplatin and the chemicals that inhibit the FA pathway in FA pathway-deficient/proficient ovarian cancer cells

From: Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin

 

Interaction with cisplatin

2008

2008 + FANCF

Chemicals

FA-deficient

FA-proficient

CI

Interpretation

CI

Interpretation

Bortezomib

1.00 ± 0.05

Additive

0.88 ± 0.02

Moderate synergism

Lactacystin

0.90 ± 0.05

Slight synergism

1.02 ± 0.05

Additive

MG132

1.13 ± 0.04

Slight antagonism

1.13 ± 0.05

Slight antagonism

ALLN

1.17 ± 0.04

Slight antagonism

1.06 ± 0.09

Additive

5929407

1.10 ± 0.04

Additive

1.00 ± 0.04

Additive

Curcumin

0.98 ± 0.02

Additive

1.06 ± 0.02

Additive

H-9

1.08 ± 0.04

Additive

0.98 ± 0.04

Additive

Gö6976

0.63 ± 0.04

Synergism

0.68 ± 0.03

Synergism

SB218078

0.90 ± 0.05

Slight synergism

0.77 ± 0.03

Moderate synergism

UCN-01

0.83 ± 0.03

Moderate synergism

0.66 ± 0.04

Synergism

Alsterpaullone

1.05 ± 0.03

Additive

1.15 ± 0.03

Slight antagonism

Roscovitine

0.98 ± 0.03

Additive

0.98 ± 0.03

Additive

Geldanamycin

0.83 ± 0.04

Moderate synergism

0.38 ± 0.05

Synergism

17-AAG

1.06 ± 0.10

Additive

0.87 ± 0.04

Slight synergism

CA-074-Me

0.91 ± 0.03

Additive

0.78 ± 0.02

Moderate synergism

Chloroquine

0.88 ± 0.05

Slight synergism

0.72 ± 0.05

Moderate synergism

Wortmannin

1.08 ± 0.05

Additive

1.12 ± 0.05

Slight antagonism

DRB

1.08 ± 0.04

Additive

0.97 ± 0.05

Additive

HNMPA-(AM)3

0.96 ± 0.02

Additive

0.91 ± 0.03

Additive

Puromycin

1.08 ± 0.03

Additive

0.88 ± 0.04

Slight synergism

TPEN

1.16 ± 0.08

Slight antagonism

1.13 ± 0.04

Slight antagonism

5656325

0.99 ± 0.03

Additive

1.05 ± 0.05

Slight antagonism

5315179

1.14 ± 0.09

Slight antagonism

0.94 ± 0.04

Additive

7012246

1.18 ± 0.05

Slight antagonism

0.87 ± 0.04

Slight synergism

5195243

1.22 ± 0.04

Moderate antagonism

1.02 ± 0.02

Additive

5373662

1.08 ± 0.04

Additive

0.90 ± 0.04

Slight synergism

  1. Combination index (CI) at 50% killing values (mean ± SEM) calculated from isobologram at the LD50 level analyses of combination of cisplatin with each FA pathway inhibitor, performed in FA-deficient (2008) and FA-proficient (2008 + FANCF) ovarian cancer cell lines. See Figure 4 and Additional file 9: Figure S7 for details. Interpretation of combination index values: 0.10 < CI ≤ 0.30, strong synergism; 0.30 < CI ≤ 0.70, synergism; 0.70 < CI ≤ 0.85, moderate synergism; 0.85 < CI ≤ 0.90, slight synergism; 0.90 < CI ≤ 1.10, additivity; 1.10 < CI ≤ 1.20, slight antagonism; 1.20 < CI ≤ 1.45, moderate antagonism [26]. Synergism is highlighted in bold letters.